Jan 26 (Reuters) - The U.S. Food and Drug Administration approved Rockwell Medical Inc's drug for treating iron loss in chronic kidney disease patients on dialysis, sending the company's shares up about 15 percent in premarket trading.
The drug, Triferic, replaces the 5-7 mg of iron patients tend to lose during each dialysis session.
01:45 Japanese shares fall 1% as yen strengthens, Samsung presser announcements ahead12
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High8
21:52 Netflix nears 94 million subscribers 10 years after streaming launch20